The Euro tumbled closer to breaking down below 1.24 levels today afternoon as the Natural Gas Report in the US shored up inventories of 3000 BCF by another 57 BCF of NatGas in US alone. Additions of record level inventories…
See more ›
Blog Archives
US Economy: ICSC sales put on brakes, Case Schiller worst since 2006, Health back with a GOP agenda?
Though the Fed would have preferred being proved right ont he continuing recoevery its indicated fears are coming true though no Jobs number is due this Tuesday. The Weekly Goldman ICSC retail indices are on mark to losing the 3%…
See more ›
Pfizer in advanced stages to sell off animal health and infant nutrition businesses | Deal Insight
Pfizer’s Animal health business has a 19% share of market and is so profitable that industry leader Bayer would have purchased it at a tad lower than $19 bln. However the company Pfizer is een on getting rid off the…
See more ›
Tagged with: Asia, Bayer, Goldman Sachs, Groupe Danone, J P Morgan, JP Morgan, Lazard, Morgan Stanley, Nestle, Pfizer
Posted in Dealbook, Healthcare
Posted in Dealbook, Healthcare
Healthcare’s big week! Biotech gets in with two | Deal insight
Biotechnology firms locally on hand in the USA worked out quick deals in the drug development firms for leukemia and lymphoma with equity premiums likely still underbidding the valueof niche treatmets yet risky propositions. Amgen paid a 33% premium and…
See more ›
Tagged with: Amgen, Business, Celgene, Health, Micromet, Motley Fool, Munich, United States
Posted in Dealbook, Healthcare, Mergers etc, Private Equity
Posted in Dealbook, Healthcare, Mergers etc, Private Equity
Bristol Myers offers $2.5 bln for Inhibitex | Advantage Dealbook
This next Pharma deal happened in the first week of January 2012 itself as another maker of Hepatitis C drugs in Georgia recommended Bristol Myers’ $26 per share offer to its shareh olders. Shareholders will make a 160% gain over…
See more ›
Tagged with: Alcoa, Bristol, Bristol Myers, Bristol-Myers Squibb, Friday, Georgia, Gilead Sciences, Hepatitis C, Inhibitex, PSI 7977
Posted in Amitonomics, Financial Markets, Healthcare, Healthcare, US
Posted in Amitonomics, Financial Markets, Healthcare, Healthcare, US
The Big Pharma rebuilding "decade": Is Big Pharma ready for the competition?
Well frankly, after our efforts to read up and check the air pressure on the Big Pharma machines, we find the restructuring effort in each case expensive and not worth the effort for most of the time. Still we have…
See more ›
Tagged with: Alcon, Big Pharma, Johnson, Novartis, Pfizer, Pharmaceutical lobby, Sales, Synthes
Posted in Emerging Markets, Healthcare, US
Posted in Emerging Markets, Healthcare, US
After Pfizer and Merck, J&J gets up to go | Advantage Dealbook
J&J has seen better days especially with brand rebuilding taking up the better part of 2010 and Pfizer and Glaxo running away with the honors with a Genzyme bid and the GAVI alliance prizes in $ 40 bln in vaccination…
See more ›
Tagged with: Boston Scientific, Johnson & Johnson, Merrill Lynch, Pfizer, Sanofi Aventis, Schering-Plough, Synthes, West Chester Pennsylvania
Posted in Dealbook, Financial Markets, Healthcare, Healthcare, Mergers etc, US
Posted in Dealbook, Financial Markets, Healthcare, Healthcare, Mergers etc, US
Of FDI and Another Sovereign Wealth Fund weekend | swfinstitute.org, Advantage 'zyaada'
A primer on Sovereign Wealth Funds and their appetite for International Investment You have already heard this a couple of times in the bull pen before the trading day begins or read it if you have just been following it…
See more ›
Tagged with: Australia, Bank of China, Brazil, china, CIC, Citibank, GIC, Qatar, Singapore, Temasek, Vietnamiet
Posted in Amitonomics, Banking, Bonds, China, Emerging Markets, Financial Markets, Financial Services, Global, Healthcare, India, Infrastructure, O'nomics, Real estate, Retail Lifestyle, US
Posted in Amitonomics, Banking, Bonds, China, Emerging Markets, Financial Markets, Financial Services, Global, Healthcare, India, Infrastructure, O'nomics, Real estate, Retail Lifestyle, US
it's the Democrats , stupid!
Wall Street vs Main Street Even as Apple, J&J and Goldman Sachs itself came out with sterling earnings after IBM’s poor draw yesterday, Markets were shcked into a stupor by the ticker news that disclosed the SEC vote on charges…
See more ›
Tagged with: Financial Regulations, Reforms, Regulatory Reforms, SEC
Posted in Financial Markets, Healthcare, Obamanomics
Posted in Financial Markets, Healthcare, Obamanomics
| INDU | 0.00 | ||
| NASDAQ | 3498.965 | ||
| S&P 500 | 1649.60 | ||
| AMZN | 261.74 | ||
| AAPL | 445.15 | ||
| GS | 158.72 | ||
| BAC | 13.24 | ||
| JPM | 53.66 | ||
| UAL | 34.37 | ||
| MCD | 100.29 | ||
| KO | 42.24 | ||
| DIS | 65.49 | ||
| DB | 45.50 | ||
| HBC | 55.35 | ||
| COW | 25.96 | ||
| BRK.B | 0.00 |
Apple
Asia
BAC
Bank
Bank of America
Banks
Barack Obama
Business
china
Citi
Citigroup
Credit Crisis
DealBook
Deutsche Bank
ECB
Economy
Euro
European Central Bank
European Union
Eurozone
Facebook
Federal Reserve System
Finance
Financial Services
Germany
Global investing
Goldman Sachs
Greece
Gross domestic product
HSBC
India
Initial public offering
Investment Banks
JPM
J P Morgan
JP Morgan
JPMorgan Chase
Liquidity Crisis
Mergers
Morgan Stanley
Retail
UBS
United States
Wall Street
Wells Fargo